AbbVie expands Oxford R&D facility with £120m investment
AbbVie invests over £120 million in its Oxford research centre, enhancing capabilities in immunology and oncology following the acquisition of DJS Antibodies.
Știri
DJS Antibodies
DJS Antibodies
AbbVie invests over £120 million in its Oxford research centre, enhancing capabilities in immunology and oncology following the acquisition of DJS Antibodies.